Rameen Kasana
Sat, December 27, 2025 astatine 6:43 AM CST 2 min read
On the aforesaid day, Autolus Therapeutics plc (NASDAQ:AUTL) delivered preliminary information from its Phase 1 CARLYSLE trial, which demonstrated affirmative responses successful patients suffering from refractory systemic lupus erythematosus (srSLE) targeted by CAR-T compartment therapy obecabtagene autoleucel (obe-cel).
During the presumption astatine the American Society of Hematology Annual Meeting, the study’s information showed that portion 3 patients achieved implicit response, 5 patients achieved DORIS effect criteria and exhibited a median onset of 5.1 months. Nine patients were assessable for information crossed some the 50 cardinal and 100 cardinal compartment dose cohorts.
As stated by Dr. Matthias Will, the Chief Development Officer,
“Data reported from the CARLYSLE proceedings amusement an encouraging precocious complaint of DORIS responses and a heavy reset successful the B compartment compartment induced by obe-cel.”
Autolus Therapeutics plc (NASDAQ:AUTL) is simply a U.K.-based clinical-stage biopharmaceutical institution engaging successful solutions for crab and autoimmune diseases. Incorporated successful 2014, the institution is dedicated to creating “next-generation T-cell immunotherapies for crab and autoimmune diseases.”
While we admit the imaginable of AUTL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.

5 days ago
6





English (CA) ·
English (US) ·
Spanish (MX) ·